Japan's Biotech Paradox: World-Class Science, Yet a Struggling Startup Ecosystem
核心洞察
Japan ranks among the top global pharmaceutical markets and leads in basic life sciences, yet its domestic biotech startup sector lags far behind the US and China, with only 679 biomedical startups as of June 2025.
Japanese venture capital investment in biotech reached just $913 million in 2023, approximately 3% of US levels, severely limiting the ability of startups to advance clinical pipelines.
Large pharmaceutical companies like Takeda (搜索) and Astellas dominate talent and innovation, while the lifetime employment system and conservative capital markets stifle entrepreneurial risk-taking.
Japan occupies a paradoxical position in global biopharmaceuticals. It is the world's third-largest pharmaceutical market, a perennial leader in Nobel Prize-winning basic science, and the birthplace of transformative therapies including Opdivo and Leqembi. Yet beneath this gleaming surface, the country has failed to cultivate globally competitive biotech startups — a structural weakness that has eroded its new drug R&D efficiency for more than two decades.
According to OPIRS statistics, Japan ranked second globally in the number of best-selling drugs developed domestically in 2008. By 2022, it had slipped to sixth place. The root cause, industry observers argue, is a chronically underdeveloped biotech startup ecosystem.
The Numbers Tell a Stark Story
As of June 2025, Japan counted 679 biomedical startups, according to INITIAL, the country's largest venture capital enterprise database. That figure represents roughly one-seventeenth of the United States' total. China, despite starting its innovative drug push later, has seen its biotechnology-related companies swell to approximately 5,699, per Biotechgate data.
More troubling than the raw count is the shallowness of existing pipelines. A 2025 survey by the Japanese Pharmaceutical Manufacturers Association found that among 108 emerging biotech companies with drug R&D capabilities, only 235 clinical R&D projects could be identified — an average of roughly 2.5 pipelines per company. Almost no companies have advanced into late-stage clinical trials with global competitiveness. From 2013 to 2022, not a single globally approved drug originated from a Japanese domestic emerging biopharmaceutical company.
Nobuyuki Hanamura, head of IQVIA's clinical development in Japan, captured the predicament succinctly: "EBP covers two-thirds of the drugs under research globally. Although these companies are more active in the United States, China, and South Korea, there is no growth in Japan."
Capital Scarcity at the Core
The funding gap is severe. In 2023, total Japanese venture capital and corporate venture capital investment in biotech reached $913 million, compared to approximately $28 billion in the United States during the same period — Japan's investment representing only about 3% of the US figure. Even with recent government support improving the financing environment, the average single-financing scale of Japanese biotech companies remains less than one-twentieth that of US companies.
Large-scale financings are exceedingly rare. As of early 2026, 12 US biotech companies had completed financings exceeding $200 million. In Japan, over the past five years, only one biotech venture capital fund has barely reached the $200 million threshold.
Structural Barriers to Resource Flow
Japan's innovation ecosystem suffers from fundamental distribution defects. Despite ranking fifth globally in biological sciences according to the Nature Index 2024, university-derived discoveries routinely enter large pharmaceutical companies through joint research and licensing agreements rather than being advanced by biotech startups.
The talent pipeline is similarly constrained. Large pharmaceutical companies such as Takeda (搜索), Astellas, and Ono have concentrated experienced drug R&D talent under the traditional "lifetime employment system." For researchers, large companies offer stable income, mature platforms, and clear career paths — advantages that cash-constrained, high-risk startups cannot match. A Nature article noted that attracting entrepreneurial scientists to leave stable university or corporate positions remains a persistent challenge.
Capital outflows further compound the domestic gap. According to joint analysis by Dealroom and NordicNinja, approximately €33 billion in Japan-related capital flowed into European enterprises from 2019 to 2025, with the life sciences sector claiming a significant share. Japanese domestic funds, in effect, continue nourishing overseas competitors.
Even successful listings offer little relief. On December 8, 2025, the Tokyo Stock Exchange introduced new listing maintenance standards requiring growth-market companies to reach a market capitalization of at least ¥10 billion within five years of listing, with delisting as the penalty for non-compliance — a formidable challenge for listed biotech firms.
Reform Efforts Underway
Japan has begun addressing these structural shortcomings. In 2022, the government proposed the "Startup Development Five-Year Plan" aimed at building a world-class entrepreneurial cluster. In 2024, the Ministry of Economy, Trade and Industry released its "Bio Policy Action Plan," outlining four development pillars: increasing support for domestic biotech, improving CDMO industrial chain infrastructure, accelerating regenerative medicine and gene therapy industrialization, and attracting global capital and overseas talent.
Special public funds from METI, AMED, and JIC are now targeting preclinical and early-stage R&D. The government's plan calls for total public and social investment in innovative drug R&D to reach ¥23.4 trillion by fiscal year 2040.
International capital is also being courted. Firms including F-Prime, RA Capital, 4BIO, and Eight Roads have begun participating in Japanese startup investments, bringing not only funding but also global clinical development, BD, IPO, and M&A resources.
Large domestic pharmaceutical companies are playing a more active role. Takeda (搜索) has expanded university and startup collaborations through its Takeda i3 innovation center. Astellas invests via Astellas Venture Management. Ono Pharmaceutical established a ¥30 billion corporate venture capital fund focused on innovative drugs, biotechnology, and digital medicine.
Despite these initiatives, the reform remains in its infancy. Building a mature biotech ecosystem requires long-term cultivation, and closing the gap with established markets in Europe and the United States cannot be achieved in the short term. The underlying logic for breaking the deadlock, analysts note, is clear: only by opening domestic circulation of technology, talent, and capital and building a sustainable innovation ecosystem can Japan's biomedical industry achieve long-term, healthy development.